Clinical trials: Autologous Transplantation
Limbal Stem-cell Deficiency
Transplantation of Autologous Oral Mucosal Epithelial Sheets for Limbal Stem-cell Deficiency
The study purpose is to evaluate the efficacy and safety of cultivated oral mucosal epithelial sheet transplantation as a novel therapy for limbal stem cell deficiency, for which no effective approaches has thus far been…
- Trial name
- NCT02415218
- Testing
- Mucosal cell sheet transplantation
- Where
- Thailand
- Volunteers
- 6 people
- Sponsor
- Siriraj Hospital
Tooth Loss, Tooth Injury
Clinical and Radiological Evaluation of Dental Autotransplantation in the Anterior Region in Young Patients
This study aims to evaluate the clinical, radiographic, functional, and patient-reported outcomes of premolar autotransplantation used to replace anterior maxillary teeth in young patients.
- Trial name
- YATA (NCT07314580)
- Testing
- Premolar Autotransplantation
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- University of Barcelona
Multiple Myeloma and Plasma Cell Neoplasm
High-Dose Melphalan Followed by Peripheral Stem Cell Transplant in Treating Patients With Amyloidosis
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of plasma cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00002810
- Testing
- filgrastim, melphalan, bone marrow ablation with stem cell support
- Where
- United States
- Sponsor
- Temple University
Multiple Myeloma
An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients
According to international guidelines, upfront therapy for transplant eligible myeloma patients should include triplet induction containing proteasome inhibitor and immunomodulatory agent, autologous stem cell transplant, PI+Imid…
- Trial name
- IFM 2018-04 (NCT03606577)
- Testing
- Carfilzomib, Daratumumab, Lenalidomide
- Where
- 12 sites in France
- Volunteers
- 50 people
- Sponsor
- Nantes University Hospital
Multiple Myeloma
Efficacy of Sequential BCMA CAR-T Cell Therapy Following Autologous Hematopoietic Stem Cell Transplantation in Transplant-eligible Newly Diagnosed Multiple Myeloma
1. Study Title A Single-Center, Open-Label, Single-Arm Clinical Study of Sequential Anti-BCMA CAR-T Cell Therapy Following Autologous Hematopoietic Stem Cell Transplantation in Transplant-Eligible Newly Diagnosed Multiple Myeloma…
- Trial name
- AUTO-CAR-T (NCT06913192)
- Testing
- CAR-T
- Volunteers
- 50 people
- Sponsor
- Xuzhou Medical University
Lymphoma, Non-Hodgkin
Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma
This is a research study testing a new approach to treating high-risk non-Hodgkin's lymphoma consisting of an autologous hematopoietic (blood) stem cell transplant (using a patient's own hematopoietic cells) followed by a…
- Trial name
- NCT00882895
- Testing
- Stem cell infusion, TLI, Anti-thymocyte globulin
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Washington University School of Medicine
Multiple Myeloma, Newly Diagnosed Multiple Myeloma
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
The purpose of this Phase 3 study is to evaluate if BRd prolongs progression free survival (PFS) and/or improves minimal residual disease (MRD) negative status compared with DRd in participants with TI-NDMM.
- Trial name
- DREAMM-10 (NCT06679101)
- Testing
- Belantamab mafodotin, Lenalidomide, Dexamethasone
- Where
- 181 sites in United States, Argentina and 22 more
- Volunteers
- 520 people
- Sponsor
- GlaxoSmithKline
Lymphoma
Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies
Cohort 1: Patients who are less than or equal to 65 years of age. 1. To determine the disease-free survival (DFS) in the 2 arms (standard dose versus high dose rituximab) Cohort 2: Patients who are older than 65 years of age 1.
- Trial name
- NCT00472056
- Testing
- Carmustine, Etoposide, Cytarabine
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- M.D. Anderson Cancer Center
Cartilage Damage, Cartilage Disease
All Autologous Cartilage Regeneration in the Treatment of the Knee Cartilage Defects
The cartilage articular defects of the knee are extremely disabling lesions and represent one of the predisposition causes to the development of articular arthrosis.
- Trial name
- NCT04785092
- Testing
- All Autologous Cartilage Regeneration
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Istituto Ortopedico Rizzoli
Pulp Necrosis, Apical Periodontitis
CGF-Enhanced Autologous Pulp Transplantation in Mature Necrotic Teeth
This pilot clinical study evaluated the clinical, radiographic, and functional outcomes of autologous pulp transplantation combined with concentrated growth factor (CGF) in mature permanent teeth with pulp necrosis and periapical…
- Trial name
- CGF-PULP (NCT07314866)
- Testing
- Autologous Pulp Transplantation With Concentrated Growth Factor
- Where
- Turkey (Türkiye)
- Volunteers
- 6 people
- Sponsor
- Kahramanmaras Sutcu Imam University
Idiopathic Pulmonary Arterial Hypertension
Safety and Feasibility of Autologous Endothelial Progenitor Cells Transplantation in Patients With Idiopathic Pulmonary Arterial Hypertension
Recent researches indicate that impairment of vascular and endothelial homeostasis plays a major role in the initiation and development of IPAH.We have recently reported the safety and feasibility data for autologous endothelial…
- Trial name
- NCT00641836
- Testing
- Transplantation of autologous endothelial progenitor cells
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Zhejiang University
Systemic Lupus Erythematosus, Systemic Sclerosis
Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases
A subset of autoimmune diseases (ADs) in children and young adults are life-threatening and unresponsive to conventional treatments.
- Trial name
- NCT05029336
- Testing
- Depletion of CD3/CD19 in an autologous stem cell transplant
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Stephan Grupp MD PhD
Anterior Cruciate Ligament Injuries, Knee Injuries
Graft Type and Outcomes After ACL Reconstruction in Female Athletes
This prospective multicenter cohort study aims to compare clinical and functional outcomes between hamstring tendon and quadriceps tendon autografts in anterior cruciate ligament (ACL) reconstruction in female athletes.
- Trial name
- LCA-WOMEN (NCT07722104)
- Testing
- Hamstring tendon autograft ACL reconstruction, Quadriceps tendon autograft ACL reconstruction
- Where
- Spain
- Volunteers
- 82 people
- Sponsor
- Universidad Católica San Antonio de Murcia
Multiple Sclerosis
Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS)
This study is a randomized multicentre, multinational, treatment interventional study of RRMS patients with breakthrough inflammatory disease activity in spite of ongoing standard immunomodulatory medication.
- Trial name
- RAM-MS (NCT03477500)
- Testing
- Cyclophosphamide and ATG, Alemtuzumab, Cladribine Pill
- Where
- 8 sites in Denmark, Netherlands and 2 more
- Volunteers
- 100 people
- Sponsor
- Haukeland University Hospital
Multiple Myeloma, Stem Cell Transplantation
Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients
1. To evaluate the toxicity and safety of a combination of arsenic trioxide with ascorbic acid and high-dose Melphalan in patients with multiple myeloma 2.
- Trial name
- NCT00661544
- Testing
- Arsenic Trioxide, Melphalan, Ascorbic Acid
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
MInimal Residual Disease Adapted Strategy
IFM 2020-02 will enroll patients eligible for ASCT less than 66 years. All patients will receive induction based on 6 cycles (28-day) of KRD-Isatuximab (Isa-KRD), in order to achieve deep responses and high MRD negativity rates.
- Trial name
- MIDAS (NCT04934475)
- Testing
- Isatuximab, ASCT
- Where
- 73 sites in Belgium, France and 1 more
- Volunteers
- 791 people
- Sponsor
- Intergroupe Francophone du Myelome
Multiple Myeloma
2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma
The Total Therapy treatment regimens developed at the Myeloma Institute have demonstrated great improvement in treatment outcomes for multiple myeloma patients.
- Trial name
- NCT03168100
- Testing
- Elotuzumab, Lenalidomide, Dexamethasone
- Where
- United States
- Sponsor
- University of Arkansas
Multiple Myeloma, Plasma Cell Myeloma
S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis
RATIONALE: Drugs used in chemotherapy such as melphalan work in different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00064337
- Testing
- filgrastim, cyclophosphamide, dexamethasone
- Where
- 35 sites in United States
- Volunteers
- 104 people
- Sponsor
- SWOG Cancer Research Network
Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting
REAL-MS: Observational Database Study of AHSCT and MS Therapies
Multiple sclerosis (MS) is a condition in which the immune system damages the brain and spinal cord. Treatments called disease-modifying therapies can reduce inflammation and disease activity.
- Conditions
- Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive
- Trial name
- REAL-MS (NCT07899502)
- Testing
- Autologous haematopoietic stem cell transplantation (AHSCT), High-efficacy disease-modifying therapy (HE-DMT)
- Where
- 3 sites in United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- Imperial College London
Breast Neoplasm, Neoplasm Metastasis
Chemotherapy and Progenitor Cell Transplantation to Treat Inflammatory Breast Cancer
This study will evaluate the effectiveness of combination chemotherapy with paclitaxel (Taxol) and cyclophosphamide (Cytoxan), followed by high-dose melphalan and etoposide for treating inflammatory breast cancer.
- Trial name
- NCT00001507
- Testing
- Monoclonal Antibody 3A1, Monoclonal Antibody 95-5-49, Monoclonal Antibody 95-6-22
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.